2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
In Partnership With:
Conference | Gastrointestinal Cancers Symposium (ASCO GI)
Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.
Zev A. Wainberg, MD, associate professor of medicine and surgery, David Geffen School of Medicine, University of California, Los Angeles (UCLA), co-director, UCLA Gastrointestinal Oncology Program, director, Early Phase Clinical Research Program, Jonsson Comprehensive Cancer Center, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.
The FIGHT trial randomized patients with FGFR2b-positive unresectable, locally advanced or metastatic gastric/GEJ cancer to bemarituzumab, a first-in-class FGFR2b antibody, plus modified FOLFOX6 (mFOLFOX6) or mFOLFOX6 plus placebo in the first-line setting.
The results revealed that bemarituzumab plus mFOLFOX6 led to significant clinical improvements in progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) compared with mFOLFOX6 plus placebo. The median PFS was 9.5 months with bemarituzumab versus 7.4 months with placebo in the intent-to-treat population, which met the study’s primary end point. As of the data cut-off, the median OS was not reached and 12.9 months, respectively. The median ORR improved from 40% with placebo to 53% with bemarituzumab. Notably, these findings are consistent with previously reported survival rates with mFOXFOX6, concludes Wainberg.